<DOC>
	<DOCNO>NCT00611286</DOCNO>
	<brief_summary>The duration dual antiplatelet treatment ( i.e . asprin clopidogrel ) drug-eluting stent implantation highly debate . This study evaluate value extend treatment 2 year procedure compare conventional treatment accord national health institute guideline ( i.e . minimum 1 month bare metal stent 6 month drug-eluting stent ) composite endpoint death , MI stroke .</brief_summary>
	<brief_title>Synergy Between Stent Drugs Avoid Ischemic Recurrences After Percutaneous Coronary Intervention</brief_title>
	<detailed_description>This randomize , multi-center , open-label , study evaluate efficacy safety profile prolong dual antiplatelet treatment ( i.e . 2-year ) aspirin clopidogrel coronary stenting compare currently recommend antiplatelet regimen ( i.e . dual antiplatelet treatment minimum 1 month BMS 6 month DES implantation ) . As degree intimal hyperplasia ( IH ) suppression provide coronary stent system may expect influence comparison conventional versus prolong dual antiplatelet treatment ( DAT ) , patient group randomize ( BMS ) , intermediate ( Endeavor ) , moderately high ( Taxus ) high ( Xience V ) degree IH suppression minimize confound role IH suppression primary hypothesis . Patients follow-up clinical basis 1 , 6 , 12 , 18 24 month primary hypothesis every year five secondary hypothesis . In conventional dual antiplatelet therapy group receive one BMS implantation time PCI , length DAT may influence acuity clinical presentation . According CURE study ( JAMA . 2002 Nov 20 ; 288 ( 19 ) :2411-20 ) , patient present non-ST segment elevation acute coronary syndrome may felt require longer 1 month DAT . Thus , impose 1-month DAT duration PCI may regard conventional current stage . Based consideration , protocol allow extension DAT 6 month PCI conventional BMS group patient satisfy inclusion exclusion criterion CURE study discretion treat physician.Extension DAt 6 month BMS patient STEMI recommend byt allow per protocol Dual antiplatelet treatment refers use Aspirin dos range 75 325 mg/day p.o . conjunction clopidogrel ( 75 mg/day ) . Ticlopidine ( 250 mg/ twice day ) second-choice drug allow case clopidogrel well tolerate unavailable . Clopidogrel ticlopidine equipotent antiplatelet agent . Both belong class thienopyridines act inhibit P2Y12 ADP receptor platelet .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
	<criteria>1 . Males females â‰¥ 18 year age coronary artery disease low , intermediate highrisk coronary anatomy , consider suitable PCI stent placement . 2 . Subjects provide write informed consent prior initiation studyrelated procedure , prior receive preprocedural sedation agree comply protocolspecified procedure . 1 . Women pregnant . Women childbearing potential must negative pregnancy test ( urine serum HCG ) within 7 day prior randomization ; close randomization possible , within 24 hour prefer . 2 . Allergy intolerance aspirin , clopidogrel ticlopidine 3 . Subjects contraindication anticoagulation and/or increase bleed risk : Past present bleed disorder include history follow within 1 month prior randomization : clinically relevant gastrointestinal bleeding , gross ( visible ) hematuria , Planned major surgery include CABG within 1 month prior randomization . Any subject know coagulopathy , platelet disorder , history thrombocytopenia . 4 . Subjects history cancer ( limit survival ) know disease free , exception basal cell carcinoma skin . 5 . History clinically important , recent ongoing alcohol abuse drug abuse . 6 . Known platelet count &lt; 100,000/mm3 ( &lt; 100 x 109/L ) . 7 . Subjects unable give inform consent assurance complete contact 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Drug-eluting stent</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>bare metal stent</keyword>
	<keyword>landmark analysis</keyword>
	<keyword>Patients coronary artery disease</keyword>
</DOC>